Two different companies use the same three words
Search “healthcare content marketing” and the first page answers a question you probably didn’t ask. Most of it is about patients: trust, waiting rooms, appointment bookings, a clinic that wants more of them.
This post is about the other reader. You sell to the hospital, the payer, the group practice or the device maker. Your buyer is a committee with a procurement calendar, and nobody in it is your patient.
The two jobs share a phrase and share almost nothing else. Patient marketing lives or dies on reach. Your job lives on whether a clinical or compliance reviewer will let the claim through.
The rule people quote is usually the wrong one
HIPAA comes up in the first meeting, every time. It’s nearly always cited too broadly.
The Privacy Rule defines marketing at 45 CFR 164.501. The text is short: “marketing means to make a communication about a product or service that encourages recipients of the communication to purchase or use the product or service.”
Read that alone and it sounds like it covers your blog. It doesn’t. Paragraph (2) of the same definition then carves out two whole classes of communication, starting with refill reminders. The obligation next door, at 45 CFR 164.508, says “a covered entity must obtain an authorization for any use or disclosure of protected health information for marketing”. Two conditions are carrying that sentence. A covered entity, and protected health information. The section allows only two exceptions to it: a face-to-face communication, and a promotional gift of nominal value.
Your article about interoperability uses neither. Your customer story does, the moment it names a hospital and describes a patient population, and that is where the permission work starts. We wrote the collection list for that job in what to collect before a case study.
Many vendors also sign a business associate agreement. That is a contract, and it can bind you tighter than the rule text does. Read yours before you decide what a case study may say.
FDA rules are narrower than the fear around them
The second rule people reach for is the FDA’s. It’s also narrower than the fear.
21 CFR 202.1 governs prescription drug advertising. Paragraph (e)(1) requires that advertisements “present a true statement of information in brief summary relating to side effects, contraindications” and effectiveness. Paragraph (e)(5) then explains what breaks it: an ad fails when “It fails to present a fair balance between information relating to side effects and contraindications and information relating to effectiveness of the drug”.
That’s a rule about prescription drugs. It isn’t a rule about your scheduling software, your sterilisation cart or your claims platform. If your product isn’t a regulated drug, this section binds nobody at your company, and quoting it in a brief just slows the writer down.
The scope question is the whole game here. A rule that applies to one population is not a rule about your market. We check the scope line of every regulation we cite, because a heading is not the rule and a rule about drugs is not a rule about software.
Which standard actually reaches your claims
Now the standard with the widest reach, and read its scope line before you use it.
The FTC’s health products compliance guidance sets the substantiation bar for health claims. Its general rule covers “claims about the health benefits or safety of foods, dietary supplements, drugs, and other health-related products”, and those claims “require substantiation in the form of competent and reliable scientific evidence.”
The guidance is more specific than that phrase suggests. For health benefits, it says substantiation “will need to be in the form of randomized, controlled human clinical testing to meet the competent and reliable scientific standard”, and it names sample size, duration and outcome measures among the parameters the FTC weighs.
Sell software rather than a health product and the guidance is not addressed to you. The standard it describes still travels, because it’s the bar the FTC applies to health claims generally, and your customer’s reviewer knows it. So a sentence like “clinicians report faster documentation” needs a source, and a sentence like “reduces readmissions” needs a study. Those are two different purchases. One takes an afternoon. The other takes whatever your clinical team already has, or it doesn’t get written.
Where a healthcare content schedule actually goes wrong
Writing isn’t the slow part. It never is, and we set out the arithmetic for that in white paper in-house or outsourced.
In this vertical the queue has more people in it. A regulated claim reaches medical, legal and regulatory reviewers. A customer story reaches the customer’s own communications team, and hospital communications teams answer to a board. A published number reaches whoever owns the data.
Three consequences follow, and all three are scheduling facts rather than complaints.
You can’t date a piece until you know who signs it. Two reviewers with a week each is a fortnight, and it arrives after the writing, not during.
Claims and evidence age at different speeds. A study published in 2019 supports a claim in 2026 only if nothing in the guidance moved, and somebody has to check that seven-year gap.
Interviews are the bottleneck that never compresses. A clinical lead with four hours a month is the real capacity of your content programme.
What we write here, and what we don’t
We write the articles, the case studies, the white papers and the email sequences, at the rates published on this site. Healthcare work sits inside the same scope as the rest.
Three things stay outside it, and they stay outside for good reasons.
We don’t write regulatory submissions, instructions for use or clinical documentation. Different discipline, different qualification, and a marketing writer’s the wrong person for all three.
We don’t decide whether your claim clears. Your regulatory reviewer does that, and no supplier should offer to replace them.
We don’t invent the evidence. Where a claim needs a study, the study comes from you or the claim doesn’t run. That refusal is the same one we list in what a B2B content agency actually does, and it’s the one we get argued with about most.
The four names a healthcare brief needs
A healthcare brief needs four things a general brief doesn’t, and each of them is a name or a document rather than an instruction.
Name the reviewers. Not the department, the people, and the order they read in. Three names beat one job title.
Name the evidence for every claim you want made, with a link or a PDF. A claim with no source attached is a claim you are asking a writer to invent.
Name the forbidden ground. Off-label uses, comparative claims against a named competitor, anything your counsel has already ruled out.
Name what the customer has agreed to. Written permission, the exact company name that may appear, and the numbers that may be published.
The rest of the brief is the ordinary kind, and how to brief a B2B writer covers it in ten minutes of work.
Reading this post the way we ask you to read a claim
The source list below has 4 entries. 3 are regulations, 1 is FTC guidance, and every quote above comes off the page itself rather than a summary of it.
We give no figure for how long a medical, legal and regulatory review takes. We found no published measurement with a stated sample. Vendor blogs quote weeks and months freely. None of the ones we read named a study, so we’re not passing the number on.
That’s the same test your reviewer will apply to your draft. It’s easier to pass when the writer has already applied it.
Sources
- 45 CFR 164.501, eCFR. The Privacy Rule definition of marketing. The exceptions in paragraph (2) matter as much as the definition, and they cover refill reminders and treatment communications.
- 45 CFR 164.508, eCFR. Authorization required for marketing uses of protected health information. The obligation is written on covered entities; business associates are reached through their agreements, not through this sentence.
- 21 CFR 202.1, eCFR. Prescription drug advertising, including the brief summary requirement at (e)(1) and the fair balance test at (e)(5). Prescription drugs only.
- Federal Trade Commission, Health Products Compliance Guidance. The competent and reliable scientific evidence standard, and what the FTC expects for health benefit claims. Guidance, not a regulation, and it says so.
Send us the format, the claim you want supported and the names of the people who sign it off. We come back inside one working day with a scope, a price, and a list of the claims that need evidence you don’t hold yet.